menu
    • menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||MTBR-tau","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Washington University School of Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals for E2814

    Menu

    E2814

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eisai

                            Japan arrow
                            Pharmex
                            Not Confirmed

                            Eisai

                            Japan arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E2814,Lecanemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Subject Enrolled in Phase II/III Study of Eisai’s Anti-Mtbr Tau Antibody E2814 For Dominantly Inherite...

                            Details : An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. E2814 is designed to prevent the spreading of tau seeds within the brains of affected ind...

                            Product Name : E2814

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : E2814,Lecanemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth